Mandate

Vinge advises Aleris in connection with the acquisition of Art Clinic AB

May 03, 2022 M&A

Vinge advises Aleris Sjukvård AB in connection with the acquisition of Art Clinic AB. Art Clinic AB operates four specialized clinics with five sub-practices in six regions in Sweden.

Aleris is one of Scandinavia’s leading healthcare provider with two million patient appointments per year and operates specialized care at over 130 locations in Sweden, Norway and Denmark. Aleris strengthens through the transaction its specialized healthcare within orthopedics, back surgery as well as aesthetic and reconstructive plastic surgery in Sweden.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted of Christina Kokko, Samra Baytar, Olivia Belding and Elias Bohlin (M&A), Johan Wahlbom (Competition), Christoffer Nordin, Sam Fakhraie Ardekani and Max Hetta (Agreements), Emil Lindwall (Employment), Nour Makie (Banking and Finance), Karolina Fuhrman (IT/GDPR), Frida Ställborn (Real Estate) and Jessica Henning (VDR specialist).

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026